Clinical response was achieved as early as Week 8 in UC (secondary endpoint) clinical trials1†
Clinical remission was achieved at 1 year in a UC clinical trial1‡
HISTO-ENDOSCOPIC MUCOSAL IMPROVEMENT (HEMI)
The first and only FDA-approved biologic treatment in UC to achieve HEMI1 §
DEMONSTRATED SAFETY PROFILE
The overall safety profile of STELARA® in UC at 1 year was consistent with that seen in other approved indications1
JANSSEN CAREPATH SAVINGS PROGRAM
Eligible patients pay $5 per dose.
Maximum program benefit per calendar year shall apply.
Janssen CarePath Savings Program: Eligible patients using commercial insurance to pay for their medication can save on their out-of-pocket medication costs for STELARA®. Eligible patients pay $5 per dose. Maximum program benefit per calendar year shall apply. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. Program does not cover the cost to give patients their treatment. See full eligibility requirements
CD=Crohn’s disease; UC=ulcerative colitis.
†Clinical response was defined as a decrease from baseline in the modified Mayo score by ≥30% and ≥2 points, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1.
‡Clinical remission was defined as Mayo stool frequency subscore of 0 or 1, Mayo rectal bleeding subscore of 0, and Mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability).
§HEMI was defined as combined endoscopic improvement (Mayo endoscopy subscore of 0 or 1) and histologic improvement of the colon tissue (neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue).
Reference: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.